Intrinsic and acquired resistance to antineoplastic agents has severely limited our ability to cure solid tumors. Cis-diamminedichloroplatinum (cisplatin) represents one of the most efficacious agents for the treatment of solid tumors especially testicular, ovarian, bladder, and head and neck carcinomas. Once this neutral compound enters cells, the chloride ligands are exchanged for water or hydroxyl moieties and a biologically reactive bifunctional electrophile is produced. Like most of our effective antineoplastic agents, this aquated platinum compound can react with intracellular nucleophiles. Although only approximately 1% of the intracellular drug covalently reacts with DNA, there is extensive evidence implicating genomic DNA as the critical target for its cytotoxicity (Roberts and Thomson, 1979).


Chinese Hamster Ovary Cell Chinese Hamster Ovary Cell Transfectants Transient Resistance Drug Resistance Protein Pyridoxal Kinase 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Andrews, P.A., Murphy, M.P., and Howell, S.B., 1987, Metallothionein-mediated cisplatin resistance in human ovarian carcinoma cells. Cancer Chemother. Pharmacol. 19:149–154.PubMedCrossRefGoogle Scholar
  2. Bakka, A., Endresen, L., Johnsen, A.B.S., Edminson, P.D., and Rugstad, H.E., 1981, Resistance against cis-dichlorodiammineplatinum in culture cells with high content of metallothionein. Toxicol. Appl. Pharmacol. 61:215–226.PubMedCrossRefGoogle Scholar
  3. Basu, A., and Lazo, J.S., 1990, A hypothesis regarding the protective role of metallothioneins against the toxicity of DNA interactive anticancer drugs. Toxicol. Lett. 50:123–135.PubMedCrossRefGoogle Scholar
  4. Basu, A., and Lazo, J.S., 1991, Suppression of dexamethasone-induced metallothionein expression and cis-diamminedichloroplatinum resistance by v-mos. Cancer Res. 51:893–896.PubMedGoogle Scholar
  5. Borch, R.F., 1987, The platinum anti-tumor drugs. In: G. Powis and R. Prough (Eds.), Metabolism and Action of Anti-cancer Drugs. Taylor and Francis, Ltd., London, pp. 163–193.Google Scholar
  6. Chin K-V., Chauhan, S.S., Pastan, I., and Gottesman, M.M., 1990, Regulation of mdr RNA levels in response to cytotoxic drugs in rodent cells. Cell Growth Differentiation 1:361–365.PubMedGoogle Scholar
  7. Churchich, J.E., Scholz, G., and Kwok, F., 1989, Activation of pyridoxal kinase by metallothionein. Biochem. Biophys. Acta. 996:181–186.PubMedCrossRefGoogle Scholar
  8. De, S.K, McMaster, M.T., and Andrews, G.K., 1990, Endotoxin induction of murine metallothionein gene expression. J. Biol. Chem. 265:15267–15274.PubMedGoogle Scholar
  9. Endresen, L., Bakka, A., and Rugstad, E., 1983, Increased resistance to chlorambucil in cultured cells with a high concentration of cytoplasmic metallothionein. Cancer Res. 43:2918–2926.PubMedGoogle Scholar
  10. Endresen, L., 1984, Comparison of the cytotoxic effect of prednimustine in cultured cells with high or low levels of metallothionein. Acta. Pharmacol. Toxicol. 54:49–57.CrossRefGoogle Scholar
  11. Freedman, J.H., Ciriolo, M.R., and Peisach, J., 1989, The role of glutathione in copper metabolism and toxicity. J.Biol. Chem. 264:5598–5605.PubMedGoogle Scholar
  12. Freedman, J., and Peisach, J., 1989, Intracellular copper transport in cultured hepatoma cells. Biochem. Biophys. Res. Comm. 164:134–140.PubMedCrossRefGoogle Scholar
  13. Hamer, D., 1986, Metallothionein. Annu. Rev. Biochem. 55:913–951.PubMedCrossRefGoogle Scholar
  14. Hidalgo, J., Garvey, J.S. and Armario, A., 1990, On the metallothionein, glutathione, and cysteine relationship in rat liver. J. Pharmacol. Exptl. Therap. 255:554–564.Google Scholar
  15. Jahroudi, N., Foster, R., Price-Haughey, J., Beitel, G., and Gedamu, L., 1990, Cell-type specific and differential regulation of the human metallothionein genes. J. Biol. Chem. 265:6506–6511.PubMedGoogle Scholar
  16. Kagi J.H.R., and Schaffer, A., 1988, Biochemistry of metallothionein. Biochemistry 27:8509–8515.PubMedCrossRefGoogle Scholar
  17. Kaina, B., Lohrer, H., Karin, M., and Herrlich, P., 1990, Overexpressed human metallothionein HA gene protects Chinese hamster ovary cells from killing by alkylating agents. Proc. Natl. Acad. Sci. USA 87:2710–2714.PubMedCrossRefGoogle Scholar
  18. Kelley, S.L., Basu, A., Teicher, BA, Hacker, M.P., Hamer, D.H., and Lazo, J.S., 1988, Overexpression of metallothionein confers resistance to anticancer drugs. Science 241:1813–1815.PubMedCrossRefGoogle Scholar
  19. Klaassen C.D., and Lehman-Mckeeman, L.D., 1989, Induction of metallothionein. J. Am. College Toxicol. 8:1315–1321.CrossRefGoogle Scholar
  20. Lohrer, H., Robson, T., Grindley, H., Foster, S., and Hall, A., 1990, Differential effects on cell killing in metallothionein overexpressing CHO mutant cell lines. Carcinogenesis 11:1937–1941.PubMedCrossRefGoogle Scholar
  21. Lohrer, H., and Robson, T., 1989, Overexpression of metallothionein in CHO cells and its effect on cell killing by ionizing radiation and alkylating agents. Carcinogenesis 10:2279–2284.PubMedCrossRefGoogle Scholar
  22. Margoshhes, M. and Vallee, B.L., 1957, A cadmium protein from equine kidney cortex. J. Am. Chem. Soc. 79:4813–4814.CrossRefGoogle Scholar
  23. Mason, R., Edwards, I.R., and McLarsen, S.J., 1984, Interaction of platinum with metallothionein-like ligands in the rat kidney after adminstration of cis-dichlorodiammine platinum II. Chem.-Biol. Interact. 49:165–179.PubMedCrossRefGoogle Scholar
  24. Naganuma, A., Satoh, M., Koyama, Y., and Imura, N., 1985, Protective effect of metallothionein inducing metals on the toxicity of cis-diamminedichloroplatinum in mice. Toxicol Lett 24:203–207.PubMedCrossRefGoogle Scholar
  25. Naganuma, A., Satoh, M., and Imura, N., 1987, Prevention of lethal and renal toxicity of cis-diamminedichloro-platinum(II) by induction of metallothionein synthesis without compromising its antitumor activity in mice. Cancer Res. 4:983–987.Google Scholar
  26. Nartey, N.O., Banerjee, D., and Cherian, G., 1987, Immunohistochemical localization of metallothionein in cell nucleus and cytoplasm of fetal human liver and kidney and its changes during development. Pathology 19:233–238.PubMedCrossRefGoogle Scholar
  27. Nartey, N., Cherian, M.G., and Banerjee, D., 1987, Immunohistochemical localization of metallothionein in human thyroid tumors. Am. J. Pathol. 129:177–182.PubMedGoogle Scholar
  28. Otvos, J.D., Petering, D.H., Shaw, C.F., 1989, Structure-reactivity relationships of metallothionein, a unique metal-binding protein. Comments Inorg. Chem. 9:1–34.CrossRefGoogle Scholar
  29. Roberts, J.J. and Thomson, A.J., 1979, The mechanism of action of antitumor platinum compounds. Prog. Nucleic Acid Res. Mol. Biol. 22:71–133.PubMedCrossRefGoogle Scholar
  30. Schilder, R.J., Hall, L., Monks, A, Handel, L.M., Fornace Jr., A.J., Ozols, R.F., Fojo, AT., and Hamilton, T.C., 1990, Metallothionein gene expression and resistance to cisplatin in human ovarian cancer. Int. J. Cancer 45:416–422.PubMedCrossRefGoogle Scholar
  31. Schmidt, C.J., and Hamer, D.H., 1986, Cell specificity and an effect of ras on human metallothionein gene expression. Proc. Natl. acad. Sci. USA 83:3346–3350.PubMedCrossRefGoogle Scholar
  32. Sharma, R.P., and Edwards, I.R., 1983, Cis-platinum: subcellular distribution and binding to metallothionein. Toxicol. Appl. Pharmacol 51:19–27.Google Scholar
  33. Teicher, B.A., Holden, S.A, Kelley, M.J., Shea, Th.C., Cucchi, C.A., Rosowsky, A, Henner, W.D., and Frei III, E., 1987, Characterization of a human squamous carcinoma cell line resistant to cis-diamminedichloroplatinum (II). Cancer Res. 47:388–393.PubMedGoogle Scholar
  34. Zelazowski, AJ., Garvey, J.S., and Hoeschaele, J.D., 1984 In vivo and in vitro binding of platinum to metallothionein. Arch. Biochem. Biophys. 229:246–252.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1991

Authors and Affiliations

  • John S. Lazo
    • 1
    • 2
  1. 1.Department of PharmacologyUniversity of PittsburghPittsburghUSA
  2. 2.The Experimental Therapeutics ProgramPittsburgh Cancer InstitutePittsburghUSA

Personalised recommendations